Stocks TradingCharts.com

stocks prices, charts & quotes

Free Stock Prices, Charts & Stock Price Quotes

Search
Symbol Search Browse Symbols My Charts Menu
QUICK QUOTE
QUICK CHART
F.A.Questions Suggestion Box Advertising Info Commodity Charts Forex Markets

Stocks & Financial News

Breaking financial news 24/7 courtesy of TradingCharts.com Inc. / TFC Commodity Charts

Paragon 28, Inc. Class Action: Lead Plaintiff Deadline Is November 29, 2024 Contact Robbins LLP For Information

Nov 16, 2024 (MENAFN via COMTEX) --
(MENAFN - EIN Presswire)

Robbins LLP Logo

Robbins LLP is Investigating Allegations that Paragon 28, Inc. (FNA) Misled Investors Regarding its Financial Statements

Paragon 28, Inc. (NYSE:FNA)

SAN DIEGO, CA, UNITED STATES, November 15, 2024 /EINPresswire / -- Robbins LLP reminds investors that a class action (case number 1:24-cv-02712) was filed on behalf of all persons and entities who purchased or otherwise acquired Paragon 28, Inc. (NYSE: FNA) common stock between May 5, 2024 and August 8, 2024. Paragon 28"develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace."

For more information, submit a form , email attorney Aaron Dumas, Jr. at ..., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Paragon 28, Inc. (FNA) Misled Investors Regarding its Financial Statements

According to the complaint, during the class period, defendants failed to disclose that: (1) Paragon 28's financial statements were misstated; (2) Paragon 28 lacked adequate internal controls and at times understated the extent of the issues with its internal controls; and (3) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times.

What Now: You may be eligible to participate in the class action against Paragon 28, Inc. Shareholders who want to serve as lead plaintiff for the class must submit their application to the court by November 29, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against Paragon 28, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contact:
Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
...
(800) 350-6003

Lauren Levi
Robbins LLP
email us here
Visit us on social media:
Facebook
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

MENAFN15112024003118003196ID1108891321

comtex tracking

COMTEX_459859491/2604/2024-11-16T00:22:46

Do not sell my personal information

Copyright © 2024. All market data is provided by Barchart Solutions. Information is provided "as is" and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.